(Q37153507)

18 August 2017

title

Accelerated cardiovascular disease and myocardial infarction risk in patients with the human immunodeficiency virus (English)

1 reference

18 August 2017

main subject

myocardial infarction

1 reference

based on heuristic

inferred from title

cardiovascular disease

1 reference

5

Steven E Lipshultz

1 reference

18 August 2017

Tanvi S Sharma

1

1 reference

18 August 2017

Sarah Messiah

series ordinal

2

1 reference

18 August 2017

Stacy Fisher

series ordinal

3

1 reference

18 August 2017

Tracie L Miller

series ordinal

4

1 reference

18 August 2017

publication date

1 January 2008

1 reference

Journal of the cardiometabolic syndrome

18 August 2017

published in

1 reference

18 August 2017

volume

3

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

93-97

1 reference

Coronary artery disease and human immunodeficiency virus infection

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Coronary artery lesions and human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Hypertriglyceridemia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Mitochondrial involvement in antiretroviral therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1559-4572.2008.07635.X

10.1111/J.1559-4572.2008.07635.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference